Trials / Completed
CompletedNCT04143477
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects
An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Astellas Pharma China, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of ASP015K after single-dose and multiple-dose administration in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | peficitinib | Oral |
Timeline
- Start date
- 2019-12-05
- Primary completion
- 2020-12-21
- Completion
- 2020-12-21
- First posted
- 2019-10-29
- Last updated
- 2024-10-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04143477. Inclusion in this directory is not an endorsement.